HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Colin A Espie Selected Research

Sleep Initiation and Maintenance Disorders (Insomnia)

11/2022The effect of sleep restriction therapy for insomnia on sleep pressure and arousal: a randomized controlled mechanistic trial.
1/2022Psychological and behavioural interventions in bipolar disorder that target sleep and circadian rhythms: A systematic review of randomised controlled trials.
1/2022Insomnia disorder: State of the science and challenges for the future.
1/2022The '5 principles' of good sleep health.
1/2021The acute effects of sleep restriction therapy for insomnia on circadian timing and vigilance.
1/2021Insomnia as a mediating therapeutic target for depressive symptoms: A sub-analysis of participant data from two large randomized controlled trials of a digital sleep intervention.
1/2021Implementation of a digital cognitive behavioral therapy for insomnia pathway in primary care.
1/2021Cost-effectiveness of digital cognitive behavioral therapy (Sleepio) for insomnia: a Markov simulation model in the United States.
1/2021The clinical effects of sleep restriction therapy for insomnia: A meta-analysis of randomised controlled trials.
1/2021Does adjunctive digital CBT for insomnia improve clinical outcomes in an improving access to psychological therapies service?
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Colin A Espie Research Topics

Disease

56Sleep Initiation and Maintenance Disorders (Insomnia)
11/2022 - 11/2006
3Pain (Aches)
08/2013 - 06/2004
2Migraine Disorders (Migraine)
03/2022 - 07/2018
2Paranoid Disorders (Paranoia)
10/2017 - 05/2015
2Hallucinations (Hallucination)
10/2017 - 05/2016
2Neoplasms (Cancer)
09/2010 - 10/2008
1Headache (Headaches)
03/2022
1Sleep Deprivation
01/2022
1Cognitive Dysfunction
01/2020
1Dementia (Dementias)
01/2019
1Psychotic Disorders (Schizoaffective Disorder)
05/2016
1Disorders of Excessive Somnolence (Hypersomnia)
02/2014
1Obstructive Sleep Apnea
11/2013
1Chronic Pain
08/2013
1Sleepiness
10/2012
1Epilepsy (Aura)
03/2010
1Mental Disorders (Mental Disorder)
11/2006
1Procedural Pain
06/2004

Drug/Important Bio-Agent (IBA)

9Indicators and Reagents (Reagents)IBA
02/2019 - 03/2014
3Dihydrotachysterol (AT 10)IBA
01/2020 - 05/2015
3Silver Sulfadiazine (SSD)FDA LinkGeneric
01/2018 - 11/2016
3Polymethyl Methacrylate (Sol)IBA
11/2016 - 01/2009
3SolutionsIBA
08/2013 - 10/2008
2Hypnotics and Sedatives (Sedatives)IBA
01/2021 - 11/2006
2MelatoninIBA
07/2018 - 12/2017
1N-(4-aminophenethyl)spiroperidol (NAPS)IBA
03/2022
1salicylhydroxamic acid (SHAM)IBA
12/2018
1Biological ProductsIBA
07/2018
1Antidepressive Agents (Antidepressants)IBA
12/2017
1Histamine Antagonists (Antihistamines)IBA
12/2017
1Antipsychotic Agents (Antipsychotics)IBA
12/2017
1BenzodiazepinesIBA
12/2017
1GABA-A Receptors (GABA(A) Receptor)IBA
12/2017
1Glutamine (L-Glutamine)FDA Link
11/2017
1ElementsIBA
10/2015
1Hydrocortisone (Cortisol)FDA LinkGeneric
01/2015
1Anti-Anxiety Agents (Anxiolytics)IBA
01/2015
1Starch SynthaseIBA
12/2012
1Anticonvulsants (Antiepileptic Drugs)IBA
03/2010
14-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA
12/2009

Therapy/Procedure

40Therapeutics
11/2022 - 11/2006
2Phototherapy (Light Therapy)
01/2022 - 12/2017
2Drug Therapy (Chemotherapy)
01/2021 - 01/2019
2Wearable Electronic Devices
12/2018 - 01/2018
1Homeopathy
12/2017
1Continuous Positive Airway Pressure
10/2012
1Relaxation Therapy (Relaxation Technique)
11/2006
1Hypnosis (Mesmerism)
06/2004